

ASX ANNOUNCEMENT**17 February 2026****H1 FY26 Results Notification & Webinar**

Saluda Medical, Inc. (ASX:SLD, “Saluda” or the “Company”), a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel closed-loop neuromodulation platform, is pleased to advise it will release its half year results for the period ended 31 December 2025 (“H1 FY26”) on Thursday, 26 February 2026.

The Company will host a webinar with Chief Executive Officer Barry Regan and Chief Financial Officer, Jim Erickson. The webinar will be hosted at 10:15am AEDT on the same day, Thursday, 26 February. Register for the webinar via the link below:

https://us02web.zoom.us/webinar/register/WN_DDt7li7rQ--pbKhc684U6Q

Following the presentation, participants will have the opportunity to ask questions. Investors may submit questions prior to the call to sam@nwrcommunications.com.au or do so via the Q&A function within Zoom. A replay will also be made available using the same zoom link above (~1-2 hours post completion).

This announcement has been authorised for release by Saluda Medical’s Disclosure Committee.

For more information, please contact:

Investors

James Erickson
Chief Financial Officer
investors@saludamedical.com

Sam Wells
NWR Communications
+61 (0) 427 630 152
sam@nwrcommunications.com.au

Media

Matt Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Saluda Medical

Saluda Medical, Inc. (ARBN 691 140 360) is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company’s closed-loop, dose-control platform senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. The Company’s first product, the Evoke® System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. 12-month results from the EVOKE study, the first and only prospective, multi-center, parallel-arm, double blind, randomized controlled pivotal study with a voluntary crossover arm in SCS, that demonstrated clinically superior

SALUDA MEDICAL, INC.**ARBN 691 140 360**

9401 James Ave S, Suite 132
Bloomington MN 55431, United States

pain relief to open-loop therapy, were published in The Lancet Neurology, 24-month results were published in JAMA Neurology, and 36-month data, that demonstrated sustained pain relief, were published in Regional Anesthesia and Pain Medicine. To learn more, including risks and important safety information, visit www.saludamedical.com/us/safety/. Saluda and Evoke are registered trademarks owned by Saluda Medical Pty Ltd.

Foreign Ownership Restriction

Saluda's CHESS Depositary Interests (CDIs) are issued in reliance on Regulation S under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act), and a no-action letter issued by the staff of the U.S. Securities and Exchange Commission. Accordingly, the Company's CDIs have not been, and will not be, registered under the U.S. Securities Act (except pursuant to an effective registration statement) or the securities laws of any state or other jurisdiction in the United States. The holders of Saluda's CDIs may not offer, sell, pledge, or otherwise transfer the CDIs into the United States or to, or for the account or benefit of, a "U.S. Person" (as defined in Rule 902(k) of Regulation S under the U.S. Securities Act) for a period of at least 12 months from the allotment date under the IPO, unless the resale of the CDIs is registered under the U.S. Securities Act or an exemption from registration is available.